← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePreclinical
injection Sekucinumab (injection Sekucinumab)
Jinnah Postgraduate Medical Centre·Erythrodermic Psoriasis
1 trials
Overview
Program
injection Sekucinumab
Overview
Company
Jinnah Postgraduate Medical Centre
Overview
Modality
ANTIBODY
Overview
Target
Erythrodermic Psoriasis
Overview
Indication
Erythrodermic Psoriasis
Overview
Phase
PRECLINICAL
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Nonclinical Safety Assessment of Digadoglucitol, a Novel Magnetic Resonance Imaging Contrast Agent for the Central Nervous System.. Digadoglucitol is a new macrocyclic gadolinium-based contrast agent for magnetic resonance imaging, intended to be used in central nervous system (CNS) and whole body clinical indications. The product features a unique dimeric structure with Gd(III) complexed by 2 mac…
Clinical
Safety signal
Nonclinical Safety Assessment of Digadoglucitol, a Novel Magnetic Resonance Imaging Contrast Agent for the Central Nervous System.. Digadoglucitol is a new macrocyclic gadolinium-based contrast agent for magnetic resonance imaging, intended to be used in central nervous system (CNS) and whole body clinical indications. The product features a unique dimeric structure with Gd(III) complexed by 2 mac…
Clinical
Program phase
PRECLINICAL